Source: Financial Supervisory Service DART / 2026-02-27
Disclosure Type: Large-scale Change in Sales or Profit/Loss Structure (Over 30%)
💡 3-Second Summary
Alteogen achieved a historic earnings surprise in FY2025, recording KRW 215.9 billion in revenue and KRW 106.9 billion in operating profit, driven by Keytruda SC commercialization milestones and an upfront payment from AstraZeneca.
📊 1. [Summary of Key Disclosure Content and Major Figures]
- Revenue: KRW 215,858,918,957 (+109.8% YoY)
- Operating Profit: KRW 106,900,077,097 (+320.8% YoY)
- Income Before Income Taxes: KRW 162,736,332,654 (+344.5% YoY)
- Net Income: KRW 144,335,436,091 (+137.8% YoY)
- Financial Position: Total Assets reached KRW 697.9 billion and Total Equity reached KRW 453.6 billion, significantly strengthening the balance sheet.
- Primary Drivers of Variance: Revenue and profitability growth were fueled by milestone payments from the commercialization of Keytruda SC (U.S. product name: Keytruda Qlex) and an upfront payment from the newly signed licensing agreement with AstraZeneca.
📈 2. [Expert Insight: Financial Implications for Investors]
This financial performance disclosure carries significant weight as it demonstrates that Alteogen has successfully transitioned from an R&D-focused biotech company into a commercial-stage entity capable of generating substantial cash flows.
While biotech valuations are traditionally driven by future expectations, Alteogen has begun validating its valuation with concrete financial metrics. In particular, the operating profit growth (+320.8%) vastly outstripping revenue growth (+109.8%) highlights the highly scalable, high-margin nature of technology licensing platforms. With milestone inflows from MSD for Keytruda SC and the upfront payment from AstraZeneca recognized concurrently, the company achieved an outstanding operating profit margin of approximately 49.5%.
An increase in non-operating income, including financial income, further reinforced net profitability. The accumulated cash has expanded total assets to KRW 697.9 billion, which is highly likely to serve as a robust financial buffer for funding subsequent pipeline developments. However, investors should note that revenue recognition from licensing agreements can introduce high volatility between quarters. Furthermore, as these figures are pre-audit results, verifying the finalized numbers in the upcoming official audited report remains a necessary step.
📝 Editor’s Commentary (by K-STOCK Editor)
This is a textbook demonstration of why Alteogen leads the Korean biotech platform sector. Operating profit has exploded by over 320% year-on-year, comfortably clearing the KRW 100 billion milestone. This is the moment where hard cash coming from global big pharma companies like MSD and AstraZeneca finally materializes on the balance sheet. Defying the stereotype that biotech companies only chase illusions, Alteogen generated an operating margin near 50%. As the highly anticipated fruits of Keytruda SC commercialization begin to feed into the financials, the market’s appraisal of Alteogen’s platform value enters a whole new dimension.
📢 Disclaimer & Source Information
Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!